In addition to our own drug development programs, Abzyme is currently in, and pursuing additional collaborations with pharmaceutical partners at all stages of discovery and development to further leverage our Antibody Discovery and Engineering Platforms.
Through the Triple-mode Antibody Discovery platform that mimics mammalian antibody diversification & affinity maturation processes, each discovery/optimization cycle finishes within weeks from receipt of target to optimized antibodies of various formats with desired attributes. Using our proprietary antibody generation platform, we are able to rapidly expand our proprietary pipeline by generating novel therapeutic antibodies with desired attributes against emerging targets. For certain programs, we plan to seek strategic collaborations to jointly advance antibody candidates through development and commercialization.
Abzyme Therapeutics has a portfolio of well-characterized modular antibodies. Through a “plug-and-play” process, an existing traditional IgG antibody can be rapidly transformed into a well-expressing Abz2 bispecific with a completely normal IgG structure. This creates a multitude of opportunities for developing novel biologics with improved therapeutic indices. Abz2 TfR Bispecifics Technology is available for licensing to develop antibodies capable of overcoming the blood-brain barrier. Abz2 CD3 Bispecifics Technology is available for licensing to develop T-cell engaging bispecific antibodies for oncology and immuno-oncology targets.